Article Data

  • Views 520
  • Dowloads 108

Original Research

Open Access

The prognostic impact of zoledronic acid in patients with early breast cancer: systematic assessment

  • J.P. Long1
  • W. Deng1
  • X.F. Ma1,*,
  • H.Y. Mao1
  • X.Y. Du1

1Department of Breast, Maternal and Child Health Hospital of Gansu, Lanzhou, China

DOI: 10.12892/ejgo3633.2017 Vol.38,Issue 5,October 2017 pp.685-689

Published: 10 October 2017

*Corresponding Author(s): X.F. Ma E-mail: jpxfcn@163.com

Abstract

Objective: The aim of this study was to assess the effectiveness of zoledronic acid in patients with early breast cancer. Materials and Methods: All randomized controlled trials (RCTs) on zoledronic acid for patients with early breast cancer were retrieved from databases including Cochrane Library, MEDLINE, EMBASE, CBMdisc, VIP, and Wanfang databases. RCTs meeting inclusive criteria were included, the data were extracted, quality was evaluated, and cross-checked by two reviewers independently according to Cochrane Handbook for Systematic Reviews of Interventions, and then meta-analyses were conducted using RevMan 5.1 software. A total of eight eligible studies met the search criteria and were evaluated. Results: With respect to follow-up time of five or more years, compared with the control arm, zoledronic acid could significantly improve overall survival rate (odds ratio (OR) = 1.19, 95% confidence interval (CI) 1.02-1.40, p = 0.03); zoledronic acid therapy also had a clear effect on frature events (OR, 0.72, 95% CI, 0.57 to 0.92, p = 0.01); Low level estrogen subgroup analysis indicated that zoledronic acid therapy showed a great beneficial effect on disease recurrence and bone metastasis (OR = 0.66, 95%CI (0.52, 0.84), p = 0.0009, OR = 0.79, 95%CI (0.63, 0.98), p = 0.03, respectively). Conclusion: Compared with the control arm, zoledronic acid significantly improve overall survival. Its clinical benefit is likely to be comprehensive results from reducing the rate of fracture and antitumor effect; zoledronic acid can decrease the recurrence rate and bone metastasis rate at low levels of estrogen; low estrogen is a key factor of the anti-tumor effects. This conclusion should be further proved by conducting more highquality, large-scale RCTs.

Keywords

Zoledronic acid; Early breast cancer; Overall survival; Recurrence rate; Bone metastasis; Meta-analysis.

Cite and Share

J.P. Long,W. Deng,X.F. Ma,H.Y. Mao,X.Y. Du. The prognostic impact of zoledronic acid in patients with early breast cancer: systematic assessment. European Journal of Gynaecological Oncology. 2017. 38(5);685-689.

References

[1] Varghese J.S., Thompson D.J., Michailidou K., Lindström S., Turnbull C., Brown J. et al.: “Mammographic breast density and breast cancer: evidence of a shared genetic basis”. Cancer Res., 2012, 72, 1478.

[2] Martinson H.A., Lyons T.R., Giles E.D., Borges V.F., Schedin P.: “Developmental windows of breast cancer risk provide opportunities for targeted chemoprevention”. Exp. Cell. Res., 2013, 319, 1671.

[3] Bodai B.I., Tuso P.: “Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations”. Perm. J., 2015, 19, 48.

[4] Thompson A., Brennan K., Cox A., Gee J., Harcourt D., Harris A. et al.: “Evaluation of the current knowledge limitations in breast cancer research: a gap analysis”. Breast Cancer Res., 2008, 10, R26.

[5] Zhao X., Xu X., Zhang Q., Jia Z., Sun S., Zhang J. et al.: “Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving “metronomic” zoledronic acid”. BMC Cancer, 2011, 11, 403.

[6] Valachis A., Polyzos N.P., Coleman R.E., Gnant M., Eidtmann H., Brufsky A.M. et al.: “Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis”. Oncologist, 2013, 18, 353.

[7] Eidtmann H., de Boer R., Bundred N., Llombart-Cussac A., Davidson N., Neven P. et al.: “Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study”. Ann. Oncol., 2010, 21, 2188.

[8] Coleman R.E., Marshall H., Cameron D., Dodwell D., Burkinshaw R., Keane M. et al.: “Breast-cancer adjuvant therapy with zoledronic acid”. N. Engl. J. Med., 2011, 365, 1396.

[9] Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Pöstlberger S., Menzel C. et al.: “Endocrine therapy plus zoledronic acid in premenopausal breast cancer”. N. Engl. J. Med., 2009, 360, 679.

[10] Hadji P., Coleman R., Gnant M., Green J.: “The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis”. Ann. Oncol., 2012, 23, 2782.

[11] Huang W.W., Huang C., Liu J., Zheng H.Y., Lin L.: “Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis”. PLoS One, 2012, 7, e40783.

[12] Valachis A., Nearchou A., Polyzos N.P., Lind P.: “Cardiac toxicity in breast cancer patients treated with dual HER2 blockade”. Int. J. Cancer, 2013, 133, 2245.

[13] Gnant M., Mlineritsch B., Stoeger H., Luschin-Ebengreuth G., Heck D., Menzel C. et al.: “Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62- month follow-up from the ABCSG-12 randomised trial”. Lancet Oncol., 2011, 12, 631.

[14] Eidtmann H., de Boer R., Bundred N., Llombart-Cussac A., Davidson N., Neven P. et al.: “Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST”. Cancer Res., 2009, 69, 4082.

[15] Coleman R., de Boer R., Eidtmann H., Llombart A., Davidson N., Neven P. et al.: “Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZOFAST study): final 60-month results”. Ann. Oncol., 2013, 24, 398.

[16] Brufsky A.M., Harker W.G., Beck J.T., Bosserman L., Vogel C., Seidler

C. et al.: “Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole”. Cancer, 2012, 118, 1192.

[17] Aft R., Naughton M., Trinkaus K., Watson M., Ylagan L., Chavez- MacGregor M. et al.: “Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial”. Lancet Oncol., 2010, 11, 421.

[18] Leal T., Tevaarwerk A., Love R., Stewart J., Binkley N., Eickhoff J. et al.: “Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer”. Clin. Breast Cancer, 2010, 10, 471.

[19] Westbrook K., Stearns V.: “Pharmacogenomics of breast cancer therapy: an update”. Pharmacol. Ther., 2013, 139, 1.

[20] Wong M., Pavlakis N.: “Optimal management of bone metastases in breast cancer patients”. Breast Cancer (Dove Med Press), 2011, 3, 35.

[21] Muralidharan A., Smith M.T.: “Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments”. Inflammopharmacology, 2013, 21, 339.

[22] Guise T.A.: “Breast cancer bone metastases: it’s all about the neighborhood”. Cell, 2013, 154, 957.

[23] Hue T.F., Cummings S.R., Cauley J.A., Bauer D.C., Ensrud K.E., Barrett-Connor E. et al.: “Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid”. JAMA Intern. Med., 2014, 174, 1550.

[24] Jeong J., Lee K.S., Choi Y.K., Oh Y.J., Lee H.D.: “Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells”. J. Korean Med. Sci., 2011, 26, 1569.

[25] Espinoza I., Liu H., Busby R., Lupu R.: “CCN1, a candidate target for zoledronic acid treatment in breast cancer”. Mol. Cancer Ther., 2011, 10, 732.

[26] Rathbone E.J., Brown J.E., Marshall H.C., Collinson M., Liversedge V., Murden G.A. et al.: “Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04)”. J. Clin. Oncol., 2013, 31, 2685.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top